<SEC-DOCUMENT>0001193125-23-269809.txt : 20231103
<SEC-HEADER>0001193125-23-269809.hdr.sgml : 20231103
<ACCEPTANCE-DATETIME>20231103060658
ACCESSION NUMBER:		0001193125-23-269809
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20231103
FILED AS OF DATE:		20231103
DATE AS OF CHANGE:		20231103

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		231374397

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d881452d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated November 3, 2023 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 33, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form
40-F&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(1):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(7):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing
the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><A HREF="d881452dex991.htm">Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer
</A></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: November 3, 2023 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d881452dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g881452dsp4a.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Announces New Biomarker Data from <FONT STYLE="white-space:nowrap">TACTI-002</FONT> Phase II </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>in First Line <FONT STYLE="white-space:nowrap">Non-Small</FONT> Cell Lung Cancer&#8195; </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Statistically significant increases of Th1 biomarkers <FONT STYLE="white-space:nowrap">(IFN-gamma,</FONT> <FONT
STYLE="white-space:nowrap">CXCL-10),</FONT> circulating immune cells (lymphocytes), and RNA levels of immune activating genes were observed and linked to improved clinical outcomes </I></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Early increase in absolute lymphocyte count is </I><I>correlated with the </I>positive Overall Survival
results in <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer patients recently reported at ESMO 2023, and is <I>a potential <FONT STYLE="white-space:nowrap">on-treatment</FONT> biomarker for clinical benefit</I>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>S</I><I>i</I><I>milar immune response biomarkers in </I><I>the </I><I>blood </I><I>were seen in the
double-blind, r</I><I>andomized</I><I> AIPAC Phase </I><I>IIb</I><I> trial, which</I><I> combined efti with chemotherapy alone and</I><I> did not include any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT>
therapy </I> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; 3</B><B></B><B>&nbsp;November </B><B>2023 &#150;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ:
IMMP) (&#147;Immutep&#148; or &#147;the Company&#148;), a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapies for cancer and autoimmune disease, today announces new biomarker data from
the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">TACTI-002/KEYNOTE-798</FONT></FONT> Phase II trial evaluating eftilagimod alpha (&#147;efti&#148;), a soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> MHC Class&nbsp;II agonist administered subcutaneously, in combination with MSD&#146;s (Merck&nbsp;&amp; Co., Inc., Rahway, NJ., USA) <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab) as first-line treatment for patients with previously untreated
unresectable or metastatic <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The biomarker data related to blood samples from <FONT
STYLE="white-space:nowrap">TACTI-002</FONT> patients to be presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting substantiates efti&#146;s unique immune system stimulation and can be linked to its success in first line
treatment of metastatic NSCLC patients, including the positive <U>Overall Survival results recently reported at ESMO Congress 2023</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dr Frederic
Triebel, Immutep CSO, said,</B> &#147;Immunomonitoring of blood cells is of prime importance when one would like to understand the effect of a systemic immunostimulant injected subcutaneously, like efti is. Importantly, the pharmacodynamic data from
efti in combination with pembrolizumab is associated with the <FONT STYLE="white-space:nowrap">35.5-month</FONT> median Overall Survival in first-line treatment of metastatic <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer
patients expressing <FONT STYLE="white-space:nowrap">PD-L1</FONT> (TPS <U>&gt;</U>1%) that we recently reported at ESMO 2023. Similar to the immune response biomarker data seen in efti&#146;s double-blind, randomized Phase IIb trial in HER2-/HR+
metastatic breast cancer, this data further confirms efti&#146;s unique stimulation of the immune system, which may help patients live longer.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sustained and significant increase of interferon-gamma (IFN-<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>) and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">C-X-C</FONT></FONT> motif chemokine ligand 10 (CXCL10) serum biomarkers for systemic Th1 response were seen at three months and six months <FONT STYLE="white-space:nowrap">on-therapy.</FONT> Among patients with a partial
or complete response, 86% (6/7) showed a <FONT STYLE="white-space:nowrap">&#8805;1.4-fold</FONT> change of IFN-<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> and 100% (7/7) showed a <FONT STYLE="white-space:nowrap">&#8805;1.4-fold</FONT> change
CXCL10, after the first efti dosing. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g881452dsp4a.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, the early increase of absolute lymphocyte count (ALC) was significantly greater in patients
that experienced a clinical benefit (e.g., overall survival, progression-free survival, complete response, partial response, stable disease), and is a potential <FONT STYLE="white-space:nowrap">on-treatment</FONT> biomarker for response to this
therapy. Furthermore, blood-based gene expression profiling (GEP) analyses revealed significant enrichment of genes involved in immune activation and cytotoxicity, including CD8 T cells, in patients with a favourable tumor response. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This biomarker data from the <FONT STYLE="white-space:nowrap">TACTI-002</FONT> Phase II is similar to the&nbsp;<U>biomarker analysis from Immutep&#146;s
randomized, double-blind AIPAC Phase IIb trial</U> in HER2-/HR+ metastatic breast cancer, which combined efti solely with paclitaxel chemotherapy and did not include any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy. In that trial, the number of circulating immune cells (monocytes, activated CD8 T cells) and CXCL10 serum levels with efti increased in a
statistically significant fashion compared to baseline. The increase in pharmacodynamic markers, including ALC and CD8 T Cells, were also significantly linked to improved overall survival in the efti group. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The poster titled &#147;Biomarker results from the 1st line <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer cohort of <FONT
STYLE="white-space:nowrap">TACTI-002:</FONT> pharmacodynamic effects of combining eftilagimod alpha (soluble <FONT STYLE="white-space:nowrap">LAG-3)</FONT> and pembrolizumab&#148; will be available on the&nbsp;<U>Posters&nbsp;&amp;
Publications</U>&nbsp;section of Immutep&#146;s website following its presentation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> is
a registered trademark of Merck Sharp&nbsp;&amp; Dohme LLC, a subsidiary of Merck&nbsp;&amp; Co., Inc., Rahway, NJ, USA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Eftilagimod Alpha
(Efti) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is Immutep&#146;s proprietary soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein and MHC Class&nbsp;II agonist that stimulates
both innate and adaptive immunity for the treatment of cancer. As a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting cell (APC) activator, efti binds to MHC (major histocompatibility
complex) Class&nbsp;II molecules on APC leading to activation and proliferation of CD8+ cytotoxic T cells, CD4+ helper T cells, dendritic cells, NK cells, and monocytes. It also upregulates the expression of key biological molecules like IFN-<FONT
STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT> and CXCL10 that further boost the immune system&#146;s ability to fight cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is under evaluation for a
variety of solid tumours including <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and metastatic breast cancer. Its favourable safety profile enables various combinations,
including with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-[L]1</FONT></FONT> immunotherapy and/or chemotherapy. Efti has received Fast Track Designation in 1st line HNSCC and in 1st line NSCLC from the United States
Food and Drug Administration (FDA). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapy for cancer and autoimmune
disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation <FONT STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and our diversified product portfolio
harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information,
please visit <U>www.immutep.com</U>. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g881452dsp4a.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong, Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268;
<U>cstrong@citadelmagnus.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Investors/Media: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Basta, VP, Investor Relations and Corporate Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; <U>chris.basta@immutep.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">This announcement was authorised for release by the Board of Immutep Limited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level&nbsp;33, Australia Square, 264 George Street, Sydney NSW 2000, Australia </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g881452dsp4a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g881452dsp4a.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$  @&!@<&!0@'!P<*"0@*#18.#0P,#1L3%! 6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$ :(   $% 0$! 0$!           ! @,$!08'" D*"P$  P$!
M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H .E
M%>[OK:QB\VYF6)/4]_I2;2W)E)1W,I?%VD-(%\]@/4QG%1[2)C]8IFU%-'-&
MLD3AT89#*<@U:=]C=--70^F,* "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@#D]?\ &L>B:NEB;-I0 #(X?&,^@QS0!U2-N0,.A&:
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M.TF0D<C']: .7^(^K2":#2HW(CV^;*!_$<\#],T 6= \+^'TTN&74989KF5
MS!IL!,]A@T <MJ<:^&?% DTV<21QD21E6SP?X2?S% '7?$=UD\/V4B_=:<$?
M]\F@"IX-\+Z1JNA?:KRU\R4R,N=[#@?0T 9GC+PK%H2PWMBSBW=MI5CDHW48
M/IQ0!VO@O5I-6\/QO,Q::%C$['JV.A_(B@#H: "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H #TH \X\7?\C#)_NK_*N>I\
M1YE?^(='XK_Y%L?[R5<_A.JO_"(? W_(-N/^NO\ 044MB<)\+*7CO_CYLO\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MFV$.EV$-G;C$42X'J?4F@"W0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MF,VW<#P<>AH Z&@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ P* #% !0 4 &!Z4 &* "@ Q0 4 &* "@ H
M* # H ,4 &!Z4 &* #% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!2_M?3O^?ZW_[^
MK_C2YD1[2'</[7T[_G^M_P#OZO\ C1S(/:0[A_:^G?\ /];_ /?U?\:.9![2
M'</[7T[_ )_K?_OZO^-',@]I#N']KZ=_S_6__?U?\:.9![2'</[7T[_G^M_^
M_J_XT<R#VD.X?VOIW_/];_\ ?U?\:.9![2'</[7T[_G^M_\ OZO^-',@]I#N
M']KZ=_S_ %O_ -_5_P :.9![2'</[7T[_G^M_P#OZO\ C1S(/:0[A_:^G?\
M/];_ /?U?\:.9![2'</[7T[_ )_K?_OZO^-',@]I#N']KZ=_S_6__?U?\:.9
M![2'</[7T[_G^M_^_J_XT<R#VD.X?VOIW_/];_\ ?U?\:.9![2'</[7T[_G^
MM_\ OZO^-',@]I#N']KZ=_S_ %O_ -_5_P :.9![2'</[7T[_G^M_P#OZO\
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M#N']KZ=_S_6__?U?\:.9![2'</[7T[_G^M_^_J_XT<R#VD.X?VOIW_/];_\
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M/JU0/^$1U?\ YXI_W\%'LY!]6J!_PB.K_P#/%/\ OX*/9R#ZM4#_ (1'5_\
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M[^"CV<@^K5 _X1'5_P#GBG_?P4>SD'U:H'_"(ZO_ ,\4_P"_@H]G(/JU0/\
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MQ3_OX*/9R#ZM4#_A$=7_ .>*?]_!1[.0?5J@?\(CJ_\ SQ3_ +^"CV<@^K5
M_P"$1U?_ )XI_P!_!1[.0?5J@?\ "(ZO_P \4_[^"CV<@^K5 _X1'5_^>*?]
M_!1[.0?5J@?\(CJ__/%/^_@H]G(/JU0/^$1U?_GBG_?P4>SD'U:H'_"(ZO\
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BB.K_ //%/^_@H]G(/JU0/^$1U?\ YXI_W\%'LY!]6J'_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
